Daily BriefsIndia

Daily Brief India: Hexaware Technologies, Alkem Laboratories Ltd, Vishnu Chemicals and more

In today’s briefing:

  • Hexaware Technologies IPO – Not Cheap on Its Own, but Peers Are Trading a Lot Higher
  • Alkem Laboratories Ltd (ALKEM IN): Shifting Focus to Chronic Segment to Yield Result in Long-Term
  • Vishnu Chemicals Limited: Q3 FY25 Update


Hexaware Technologies IPO – Not Cheap on Its Own, but Peers Are Trading a Lot Higher

By Clarence Chu

  • Hexaware Technologies (HEXW IN) is looking to raise US$1bn from its India IPO.
  • Hexaware is a global digital and technology services company with AI at its core, delivering innovative solutions that help customers in their digital transformation journey and subsequent operations.
  • In this note, we discuss its RHP updates, undertake a peer comparison and share our thoughts on valuation.

Alkem Laboratories Ltd (ALKEM IN): Shifting Focus to Chronic Segment to Yield Result in Long-Term

By Tina Banerjee

  • Alkem Laboratories Ltd (ALKEM IN) has announced twin acquisitions in medical devices and dermatology space. The acquisitions will further strengthen Alkem’s positioning in the domestic market.
  • Alkem has reported Q3FY25 result, with mainstay domestic business showing 6% YoY growth. EBITDA margin improved to 22.5% (Q3FY24: 21.3% and Q2FY25: 22.0%).
  • Alkem’s inclination toward acute and NELM segments has been a reason for its historically cheaper valuation. However, with portfolio expansion toward high-margin chronic segment should place Alkem for re-rating.

Vishnu Chemicals Limited: Q3 FY25 Update

By Sudarshan Bhandari

  • Vishnu Chemicals (VCL IN) posted strong Q3 financials with 22% revenue, 55% EBITDA, and 66% PAT YoY growth; new capex in chromium and expansion of barium, Strontium Carbonate production underway.
  • Capacity of chromium has potential to operate at 90% utilization level, where Barium segment is operating at  60-70%, can be used till 80-85%.
  • Company is plan to gain market share in US due to reduced competition.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars